Alzheimer's disease - A history of almost 100 years;Alzheimers sjukdom - En snart hundraårig historia

Lakartidningen

Volumn 101, Issue 50, 2004, Pages 4125-4132

  Gustafson, Lars ^a   Brun, Arne ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; HUMAN; MEDICAL ASSESSMENT; PATHOGENESIS; PROTEIN PHOSPHORYLATION; REVIEW; TEMPORAL CORTEX;

ALZHEIMER DISEASE; GERMANY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; PERIODICALS; PUBLIC OPINION; SWEDEN;

EID: 10644271584     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Binswanger O. Die Abgrenzung der allgemeinen progressiven Paralyse. Berliner Klinische Wochenschrift 1894;31:1103-5, 1137-9, 1180-6.
2. Alzheimer A. Über eine Eigenartige erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin, Berlin 1907:64:146-8.
3. Kraepelin E. Psychiatrie: Ein Eehrbuch für Studierende und Ärtzte. Eeipzig: Verlag von Johann Ambrosius Barth; 1910.
4. Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. Zeitschrift für die Gesamte Neurologie und Psychiatrie 1911;4:356-85.
5. Brun A, Englund E, Gustafson E, Passant U, Mann DMA, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994;57:416-8.
6. Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M, editor. Handbuch der Neurologie. Volume 3. Berlin: Springer; 1912. p. 920-33.
7. Wigert V. Översikt av de histologiska förändringarna i hjärnbarken hos seniltdementa jämte beskrivning av ett fall av Alzheimers sjukdom. Läkartidningen 1913;10:1337-60.
8. Gellerstedt N. Zur kenntnis der Hirnveränderungen bei der normaler Altersinvolution. Uppsala Läkarförenings Förhandlingar 1933;38:193-404.
9. Delay J, Brion S. Les démences tardives. Paris: Massen; 1962.
10. Sourander P, Sjögren H. The concept of Alzheimer's disease and its clinical implications. In: Wolstenholme GEW, O'Connor M, editors. Alzheimer's disease and related conditions. London: J & A Churchill; 1970. p. 11-36.
11. Lauter H. Über Spätformen der Alzheimerschen Krankheit und ihre Beziehung zur senilen Demenz. Psychiatr Clin (Basel) 1970;3:169-89.
12. Brun A, Gustafson L, Mitelman F. Normal chromosome banding pattern in Alzheimer's disease. Gerontology 1978;24:369-72.
13. Tanzi RE, St George-Hyslop PH, Haines JL, Polinsky RJ, Nee L, Foncin JF, et al. The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid beta-protein gene. Nature 1987;329:156-7.
14. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987;235:877-80.
15. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992;1:345-7.
16. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The »Arctic« APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001;4:887-93.
17. Hutton M, Busfield F, Wragg M, Crook R, Perez-Tur J, Clark RF, et al. Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. Neuroreport 1996;7:801-5.
18. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS. et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-81.
19. Nordstedt C, Lake S, Winblad B. Alzheimers sjukdom - en amyloidsjukdom i hjärnan. Läkartidningen 1992;89:4255-60.
20. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98.
21. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
22. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990;250:279-82.
23. Blass JP, Gibson GE, Hoyer S. The role of the metabolic lesion in Alzheimer's disease. J Alzheimers Dis 2002;4:225-32.
24. Terry RD. The fine structure of neurofibrillary tangles in Alzheimer's disease. J Neuropathol Exp Neurol 1963;22:629-42.
25. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 1963;197:192-3.
26. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001;24:87-97.
27. Brun A, Gustafson L. Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study. Arch für Psychiatric Nervenkrankheiten 1976;223:1533.
28. Gustafson L, Brun A, Ingvar DH. Presenile dementia: clinical symptoms, pathoanatomical findings and cerebral blood flow. In: Meyer JS, Lechner H, Reivich M, editors. Cerebral vascular disease. Amsterdam: Excerpta Medica; 1977. p. 5-9.
29. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59.
30. Lassen NA, Ingvar DH. Radioisotopic assessment of regional cerebral blood flow. Progress in Nuclear Medicine 1972;1:376-409.
31. Risberg J, Ingvar DH. Patterns of activation in the grey matter of the dominant hemisphere during memorizing and reasoning. A study of regional cerebral blood flow changes during psychological testing in a group of neurologically normal patients. Brain 1973;96:737-56.
32. Brun A, Gustafson L. Limbic lobe involvement in presenile dementia. Archiv für Psychiatrie Nervenkrankheitetn 1978;226:79-93.
33. Minoshima S, Giordani B, Berent S, Frey KA, Foster NE, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
34. Wallin A, editor. Konsensus om demenssjukdomar (I): Klassifikation och utredning. Läkartidningen 1990;87:3856-65.
35. Wallin A, editor. Konsensus om demenssjukdomar (II): Utredning och speciell diagnostik. Läkartidningen 1990;87:4443-8.
36. Wallin A, Brun A, Gustafson E. Swedish consensus on dementia diseases. Acta Neurologica Scandinavica 1994;90:1-31.
37. Englund E, Brun A. A white matter disorder: common dementia of the Alzheimer's type. J Clin Exp Neuropsychol 1985;7:168-9.
38. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986;19:253-62.
39. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen EA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
40. Londos E, Passant U, Brun A, Rosen I, Risberg J, Gustafson E. Regional cerebral blood flow and EEG in clinically diagnosed dementia with Lewy bodies and Alzheimer's disease. Arch Gerontol Geriatr 2003;36:231-45.
41. Londos E. Dementia with Lewy bodies - a clinical and neuropathological approach. Lund: Department of Clinial Neuroscience. Lund University; 2001.
42. Gottfries C. Störningar i monoaminomsättningen vid organisk presenil demens och senil demens. Läkartidningen 1974;71:1284-5.
43. Adolfsson R, Gottfries CG, Roos BE, Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 1979;135:216-23.
44. Ingvar DH. Demens. Patofysiologi och klinik. Läkartidningen 1974;71:1267-306.
45. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976;99:459-96.
46. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
47. Whitehouse PJ, Price DE, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9.
48. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30:113-21.
49. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315:1241-5.
50. Minthon L, Nilsson K, Edvinsson L, Wendt PE, Gustafson L. Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. Dementia 1995;6:245-51.
51. Minthon L, Gustafson L, Dalfelt G, Hagberg B, Nilsson K, Risberg J, et al. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993;4:32-42.
52. Hardy J, Cowburn R, Barton A, Reynolds G, Dodd P, Wester P, et al. A disorder of cortical GABAergic innervation in Alzheimer's disease. Neurosci Lett 1987;73:192-6.
53. Nordberg A, Adem A, Hardy J, Winblad B. Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci Lett 1988;86:317-21.
54. Annerstedt L, Fournier K, Gustafson L, Hallén U, Malmkvist I, Salö S, et al. Demensanpassat boende. Medicinsk kompetens nödvändig vid planering. Läkartidningen 1992;89:2285-91.